Evidence map›Paper›PMID 38478462›Full record

Trial reportGut microbes

Long- and short-term effects of fecal microbiota transplantation on antibiotic resistance genes: results from a randomized placebo-controlled trial.

Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Mohammad H Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo and 8 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Mapping 25 years of research on gut microbiota and antibiotic resistance: bibliometric insights and future directions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  7. Review
  8. Review
  9. FMT alleviates multidrug-resistantFrontiers in microbiology · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Armin RashidiClinical Research Division, Fred Hutchinson Cancer Center and Division of Oncology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-9384-272X
Maryam EbadiDepartment of Radiation Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA.
Tauseef Ur RehmanDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Heba ElhusseiniDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
David KazadiDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Hossam HalaweishDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Mohammad H KhanDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Andrea HoeschenDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Qing CaoBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Xianghua LuoBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Amanda J KabageDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Sharon LopezDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Shernan G HoltanDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Daniel J WeisdorfDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Chang LiuDepartment of Soil, Water, and Climate, BioTechnology Institute, University of Minnesota, MN, USA.
Satoshi IshiiDepartment of Soil, Water, and Climate, BioTechnology Institute, University of Minnesota, MN, USA.
Alexander KhorutsDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Christopher StaleyDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · USUniversity of Washington · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Institutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3M
NCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR002494
6 · The paper itself

Abstract

In small series, third-party fecal microbiota transplantation (FMT) has been successful in decolonizing the gut from clinically relevant antibiotic resistance genes (ARGs). Less is known about the short- and long-term effects of FMT on larger panels of ARGs. We analyzed 226 pre- and post-treatment stool samples from a randomized placebo-controlled trial of FMT in 100 patients undergoing allogeneic hematopoietic cell transplantation or receiving anti-leukemia induction chemotherapy for 47 ARGs. These patients have heavy antibiotic exposure and a high incidence of colonization with multidrug-resistant organisms. Samples from each patient spanned a period of up to 9 months, allowing us to describe both short- and long-term effects of FMT on ARGs, while the randomized design allowed us to distinguish between spontaneous changes vs. FMT effect. We find an overall bimodal pattern. In the first phase (days to weeks after FMT), low-level transfer of ARGs largely associated with commensal healthy donor microbiota occurs. This phase is followed by long-term resistance to new ARGs as stable communities with colonization resistance are formed after FMT. The clinical implications of these findings are likely context-dependent and require further research. In the setting of cancer and intensive therapy, long-term ARG decolonization could translate into fewer downstream infections.

Indexed as

Fecal Microbiota TransplantationGastrointestinal MicrobiomeAnti-Bacterial AgentsDrug Resistance, MicrobialFecesHumansTreatment OutcomeAnti-Bacterial AgentsAcute myeloid leukemiaantibiotic resistance genefecal microbiota transplantationhematopoietic cell transplantation

Identifiers

PMID38478462
PMCPMC10939144
OpenAlexW4392762537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.